

# Luisa Roade

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6300724/luisa-roade-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10  
papers

946  
citations

4  
h-index

15  
g-index

15  
ext. papers

1,411  
ext. citations

9.8  
avg, IF

2.82  
L-index

#	Paper	IF	Citations
10	Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up.. <i>Microbiology Spectrum</i> , <b>2022</b> , e0214921	8.9	
9	One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 462-469	6.1	4
8	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. <i>JHEP Reports</i> , <b>2021</b> , 3, 100280	10.3	0
7	Etiologies and Features of Acute Viral Hepatitis in Spain. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 1030-1037	6.9	2
6	Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. <i>Therapeutic Advances in Infectious Disease</i> , <b>2021</b> , 8, 2049936120985954	2.8	5
5	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1522-1534	59.2	913
4	An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. <i>Scientific Reports</i> , <b>2020</b> , 10, 3038	4.9	2
3	Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. <i>Liver International</i> , <b>2020</b> , 40 Suppl 1, 15-21	7.9	10
2	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1164-1169	3.3	6
1	New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations		2